JOHNSON & JOHNSON

J&J’s $5.5 billion talc settlement shifts focus to high‑margin oncology, immunology and rare‑disease R&D while cutting legal risk and aligning with value‑based reimbursement.

J&J’s modest stock rise shows investor confidence in its strategic push into the booming psychedelic‑adjacent neuroscience market, backed by smart pricing, payer engagement, and targeted M&A to drive $3‑$5 bn in first‑five‑year revenue.

Johnson & Johnson stock nudges up 1% amid market calm, showcasing resilient earnings, growing pipeline and ESG strides that may boost investor confidence.

Johnson & Johnson Q2 earnings show stable core profits and a boost from new oral anti‑PD‑L1 and dual‑target MAPK drugs, sparking upward analyst outlooks.

Johnson & Johnson’s Q2 2026 earnings reveal a strategic pivot to high‑growth oncology, fueled by Firefly Bio’s ADC platform and a premium pricing, RWE‑driven market‑access strategy. It outlines how J&J plans to navigate patent cliffs, expand in emer…

J&J Q2 earnings preview: discover how Darzalex and Carvykti drive a 2026 $100 billion sales upgrade, EPS growth, and investor upside amid macro‑economic risk.

Johnson & Johnson’s Q2 2026 earnings show strong growth, driven by consumer health, medical devices and a booming pharma pipeline, including breakthrough cell‑therapy data.

Johnson & Johnson secures FDA approval for its dual‑energy RF/PF catheter, boosting vascular device revenue while navigating pricing, competition, and patent cliffs.

Johnson & Johnson appoints Jennifer Cullen to lead U.S. veterinary nutrition, boosting pet‑health innovation and steady shareholder gains.

Johnson & Johnson’s Q1 earnings show strong pharma sales, especially oncology, modest device growth, solid margins, R&D focus, and stable dividends.